Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Oxaliplatin

Sorafenib

Antimetabolites

Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.

Gemcitabine, Oxaliplatin

Hye Jin Choi

The purpose of this study is to test the safety of gemcitabine and oxaliplatin regimen and to see its effects on sorafenib treatment failed hepatocellular carcinoma patients.

Patients who progressed after or cannot tolerate sorafenib treatment. Patients who cannot receive sorafenib for other reason are also permitted. Treatment is given in cycles, each cycle is 2 weeks long. Tumor measurements by CT and/or MRI will be repeated every 3 cycles. Patients will continue to receive study treatment as long as there is no disease progression or unacceptable side affects.

Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

Phase II Study of Gemcitabine With Oxaliplatin in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year.

Overall safety profile verified as relevance of adverse events and laboratory abnormality based on CTCAE v4.0.

Yonsei University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment	NCT05517239	Hepatocellular ...	Gemcitabine, Ox...	20 Years -	Yonsei University
Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment	NCT05517239	Hepatocellular ...	Gemcitabine, Ox...	20 Years -	Yonsei University

Spots Global Cancer Trial Database for hepatocellular carcinoma, unresectable, advanced